Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
119.6 EUR | 0.00% |
|
+2.60% | 0.00% |
07-01 | Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat | MT |
07-01 | Merck: license agreement with Orion Corp. for opevesostat | CF |
MarketScreener Strategies
Merck and Company : Leader in oncology, modest valuation | October 29, 2019 at 11:04 am |
- Stock Market
- Equities
- MRK Stock
- 0QAH Stock
- News Merck & Co., Inc.
- MarketScreener Strategies